About Psorinex

A NEW PATENTED BREAKTHROUGH
For years patients have relied on smelly tar treatments, steroids, or fully systemic biologic therapies. A group of leading doctors, chemists and researchers have studied the effects of organic supersterol – organic sterile on the symptoms of psoriasis and have seen amazing results. This natural ingredient has been discovered to relieve the painful and embarrassing symptoms of Psoriasis.

ORGANIC SUPERSTEROL
Formulated by dermatologists to provide relief and visible results to the appearance and symptoms associated with this life altering condition. This easy to apply ointment quickly absorbs into the skin providing moisture and relief to painfully itching red skin. Psorinex may help to control the super dehydration associated with the production of scaling, redness, and appearance of psoriasis.

REDUCE THE APPEARANCE OF PSORIASIS
When used daily, Psorinex goes to work to help rebalance the skin and the reaction which causes psoriatic growth. The patented formulation, which has a sealant allows for the ability to wear clothing within minutes after application.

SAFE & GENTLE
Psorinex can be applied to any area of redness day and night to help promote the return of healthy, soft and pain free skin.

Hear from our Founding Physician
Benefits
Relieves Itching
Instantly
Cracked Irritated Skin
Relieves
Moisture
Retains
Natural Skin
Restores

FRAGNANCE FREE

PARABEN FREE

ALCOHOL FREE


Non- Steroidal
Dermatologist Developed & Tested

PATENTED FORMULA

HEAL THE SKIN FROM WITHIN
Psorinex ointment is a bioactive non-drug sterol containing vitamins A and E, which has the ability to combine with the dermal layer of the skin to make it soft, supple, and moisturized. Proven efficacy for those with psoriasis. Non-toxic.

Clinical Trial Results - Before & After
Team Members
CLINICAL TEAM MEMBERS

Christopher Kyriakides, DO
PRINCIPAL EXECUTIVE
& FOUNDER
Dr. Chris Kyriakides is a board-certified practicing physiatrist for over 25 years with multiple offices, a current board member of the NYU Langone Musculoskeletal Board of Advisors, and on faculty of two New York medical schools. Beyond his clinical work, he has spearheaded ventures in academia, serving as chief executive officer of a publicly traded biotechnology company. During his tenure as CEO, Dr. Kyriakides successfully collaborated with the National Institute of Health (NIH) and National Cancer Institute (NCI) to develop a patient-specific immunotherapeutic vaccine for the treatment of B-cell lymphoma. He has been at the forefront of immunology and immunotherapy since 1998, having collaborated on multiple projects with NYU, Columbia University, University of Chicago, Duke University, University of Minnesota, and Moffitt Cancer Center.